Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global antisense & RNAi therapeutics market is expected to exhibit a CAGR of 9.50% during 2022-2027.

Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. It is also used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. It is employed for treating various respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. RNAi therapy also assists in preventing the production of specific genes that cause diseases or contribute to the growth of diseases.

Antisense & RNAi Therapeutics Market Trends:

The growing demand for antisense and RNAi therapeutics to treat uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, represents one of the key factors driving the market. Besides this, there is a rise in the demand for disease management to regulate gene expression by malfunctioning genes across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, key market players are extensively investing in research and development (R&D) activities to develop molecules based on antisense technology. They are also collaborating with contract research organizations (CROs) working on drug delivery, which is strengthening the growth of the market. In addition, the growing demand for antisense RNA to prevent disease onset and reduce disease progression is positively influencing the market. Apart from this, the rising need for curing and preventing diseases, such as cancer, human immunodeficiency virus (HIV), and other diseases caused by mutating viruses is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antisense & RNAi therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, route of administration and application.

Breakup by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA
     

Breakup by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others
     

Breakup by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Technology, Route of Administration, Application, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global antisense & RNAi therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antisense & RNAi therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Antisense & RNAi Therapeutics Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Technology
    6.1    RNA Interference
        6.1.1 Market Trends
        6.1.2 Key Segments
           6.1.2.1 siRNA
           6.1.2.2 miRNA
        6.1.3 Market Forecast
    6.2    Antisense RNA
        6.2.1 Market Trends
        6.2.2 Market Forecast
7    Market Breakup by Route of Administration
    7.1    Intravenous Route
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Subcutaneous Route
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Intrathecal Route
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Pulmonary Delivery
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Intraperitoneal Injection
        7.5.1 Market Trends
        7.5.2 Market Forecast
    7.6    Others
        7.6.1 Market Trends
        7.6.2 Market Forecast
8    Market Breakup by Application
    8.1    Oncology
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Cardiovascular Diseases (CVDs)
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Respiratory Disorders
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Renal Diseases
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Neurodegenerative Disorders
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Genetic Disorders
        8.6.1 Market Trends
        8.6.2 Market Forecast
    8.7    Infectious Diseases
        8.7.1 Market Trends
        8.7.2 Market Forecast
    8.8    Others
        8.8.1 Market Trends
        8.8.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis
12    Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Alnylam Pharmaceuticals Inc.
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    Arbutus Biopharma Corporation
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    Arrowhead Pharmaceuticals Inc.
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
        14.3.4    Benitec Biopharma Ltd.
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
           14.3.4.4 SWOT Analysis
        14.3.5    Bio-Path Holdings Inc.
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
        14.3.6    Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
        14.3.7    Ionis Pharmaceuticals Inc.
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    OliX Pharmaceuticals Inc.
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
        14.3.9    Phio Pharmaceuticals Corp.
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio
           14.3.9.3 Financials
        14.3.10    Sarepta Therapeutics Inc.
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio
           14.3.10.3 Financials
           14.3.10.4 SWOT Analysis
        14.3.11    Silence Therapeutics
           14.3.11.1 Company Overview
           14.3.11.2 Product Portfolio
           14.3.11.3 Financials
        14.3.12    Sirnaomics Inc.
           14.3.12.1 Company Overview
           14.3.12.2 Product Portfolio

List of Figures

Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2021
Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2021
Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2021
Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2021
Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2021
Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2022-2027
Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4